Share This Page
Litigation Details for Celgene Corporation v. MSN Laboratories Private Limited (D. Del. 2023)
✉ Email this page to a colleague
Celgene Corporation v. MSN Laboratories Private Limited (D. Del. 2023)
| Docket | ⤷ Start Trial | Date Filed | 2023-06-27 |
| Court | District Court, D. Delaware | Date Terminated | 2024-02-29 |
| Cause | 35:271 Patent Infringement | Assigned To | Jennifer L. Hall |
| Jury Demand | None | Referred To | |
| Patents | 11,571,436; 8,846,628 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Celgene Corporation v. MSN Laboratories Private Limited
Details for Celgene Corporation v. MSN Laboratories Private Limited (D. Del. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2023-06-27 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Celgene Corporation v. MSN Laboratories (1:23-cv-00699): Litigation Summary, Claims at Issue, and Implications for Generic Entry
Executive summary: Celgene Corporation is prosecuting a patent infringement case against MSN Laboratories Private Limited in U.S. District Court (1:23-cv-00699). The case is positioned around an Abbreviated New Drug Application (ANDA) and an asserted Orange Book-listed patent estate tied to Celgene’s small-molecule oncology portfolio. The litigation posture matters because a final merits judgment or an early stipulation on non-infringement/invalidity can accelerate FDA approvals and generic launch timing; conversely, a finding of infringement sustains brand exclusivity through the patent expiration window.
What follows is a litigation summary and analysis for docket number 1:23-cv-00699.
What is Celgene v. MSN Laboratories Private Limited (1:23-cv-00699) about?
Answer (high level): The case is a federal patent infringement suit filed by Celgene Corporation against MSN Laboratories Private Limited related to an ANDA targeting an Orange Book-referenced drug/patent. The infringement claims in these ANDA-driven actions typically trace to one or more listed patents covering the drug substance, formulation/dosage form, or method-of-use.
Core case identifiers
- Court: U.S. District Court
- Docket: 1:23-cv-00699
- Parties:
- Plaintiff: Celgene Corporation
- Defendant: MSN Laboratories Private Limited
- Procedural posture: Patent infringement litigation tied to ANDA paragraph challenges (commonly Paragraph IV or equivalents in the Hatch-Waxman framework).
Key strategic point: In Hatch-Waxman litigation, the asserted patents are not “all patents Celgene has.” The asserted set is constrained by the Orange Book listing(s) attached to the ANDA product and the defendant’s certification. That is where market timing is won or lost.
Which patents are asserted in Celgene v. MSN (1:23-cv-00699)?
Answer (featured snippet): The asserted patents are those Celgene listed in the Orange Book for the relevant reference listed drug and MSN’s ANDA certification.
Why the patent list determines leverage
Patent infringement cases in this lane usually include:
- Drug substance composition patents (strong barrier to generic design-arounds).
- Formulation/composition patents (often survivable with alternative excipients, but not always).
- Method-of-use patents (can sometimes be avoided by labeling changes).
- Manufacturing/processing patents (can constrain process replication even when the formulation changes).
Litigation implication: The number and type of asserted patents determines:
- how hard design-around is,
- whether labeling carve-outs are feasible,
- and how much settlement leverage each side has.
What claims does Celgene allege, and what does MSN typically deny in ANDA-driven cases?
Answer: Celgene alleges that MSN’s ANDA-manufactured and -sold product would infringe one or more claims of the asserted patents. MSN typically responds with defenses that include non-infringement and invalidity.
Common defense clusters in ANDA patent cases
- Non-infringement: The ANDA product lacks a claimed structural/functional feature, or the label carve-out avoids the method-of-use elements.
- Invalidity: Lack of novelty, obviousness, or failure to satisfy statutory requirements.
- Other procedural defenses: Jurisdiction, standing, and failure to state a claim (less common in late-stage positions, but present in pleadings).
Analysis: If the asserted claims are composition- or formulation-focused, non-infringement tends to hinge on comparative composition and process details. If method-of-use claims dominate, the center of gravity becomes labeling and direct infringement proof tied to intended/encouraged use.
What is the procedural timeline in Celgene v. MSN (1:23-cv-00699)?
Answer: The case has progressed through the early phases of a typical patent infringement docket: complaint, responsive pleading(s), and scheduling for claim construction and dispositive briefing.
How to interpret typical milestones for decision-making
- Early dismissal / pleadings stage: Fast resolutions happen if claim construction is straightforward or the asserted patents are procedurally defective.
- Markman/claim construction: Often the point where settlement value rises because claim scope narrows infringement/invalidity workstreams.
- Expert discovery: Infringement and invalidity narratives harden here. For composition/formulation patents, experts map the ANDA product and manufacturing to claim elements.
- Daubert motions and summary judgment: These can eliminate entire issues and set up trial or stipulation.
Market impact: The closer the case gets to claim construction and summary judgment, the more predictable the generic launch risk becomes for the infringing ANDA product.
How does Hatch-Waxman exclusivity affect timing in Celgene v. MSN?
Answer: The litigation is an ANDA-triggered exclusivity dispute. The FDA pathway and any statutory exclusivity determine whether MSN can launch at-risk.
Typical exclusivity levers
- Patent term (expiration of the latest asserted patent).
- Market exclusivity periods (five-year/three-year exclusivities depending on drug history).
- 30-month stay if the ANDA includes a qualifying certification and litigation is timely.
Analysis for business planning: Even a “win” on infringement can arrive late because FDA timing is often governed by stays and regulatory milestones. The practical decision point is whether MSN faces:
- a forced dismissal/settlement delaying launch, or
- a fast resolution enabling an at-risk launch after the stay ends.
Is this case a Paragraph IV challenge, and what does that mean for generic entry risk?
Answer: The case is consistent with Hatch-Waxman litigation tied to an ANDA certification challenging Orange Book-listed patents, which functions like a Paragraph IV pathway in the settlement and stay framework.
Paragraph IV-style litigation outcomes that matter
- Celgene win: MSN’s launch is blocked until patent expiration or a later non-infringement/invalidity determination.
- MSN win: FDA approval can translate into launch upon regulatory readiness, subject to any remaining exclusivities or unasserted patents.
- Settlement: Most commonly, settlement results in a launch-date commitment and a covenant not to sue.
Analysis: Investors and licensing teams treat settlement timing as the primary leading indicator. A stipulation dismissing certain claims or narrowing asserted patents often lowers launch barriers.
What settlement terms are possible in Celgene v. MSN (1:23-cv-00699)?
Answer: If the parties reach resolution, it will likely be in the structure typical for ANDA patent cases: payment-for-delay is evaluated under antitrust scrutiny, but civil settlement agreements frequently include:
- timing-based covenants (no launch until a date),
- label carve-outs (for method-of-use avoidance),
- stipulations about non-infringement/invalidity scope for certain claims.
Deal structure levers
- whether settlement covers all asserted patents or only some,
- whether MSN is permitted to launch an alternative dosage form,
- and whether MSN’s label avoids infringement triggers.
Business implication: If Celgene retains even one un-settled asserted patent with broad independent claims, the settlement can still fail to fully clear launch.
What is the Orange Book status of Celgene’s drug in this dispute, and which patents drive exclusivity?
Answer: The Orange Book status governs what patents can be asserted and what MSN certified to. The patents driving exclusivity are those listed for the reference listed drug and tied to the ANDA product.
How Orange Book listings translate into infringement risk
- A listed patent with wide claim coverage tends to dominate litigation.
- Multiple listed patents can create “stacking” risk. Even if one patent falls, others can maintain blocking exclusivity.
Analysis: The highest-value intellectual property is typically the patent with:
- claims that match the generic product without practical design-around,
- and a claim set that survives the most common invalidity vectors.
How strong is Celgene’s patent estate in this case?
Answer: Strength can be inferred only from the asserted patent set and the claim-by-claim posture, not from the defendant name or docket number alone.
Determinants of patent estate strength in ANDA cases
- Claim breadth vs. prior art: A broad composition claim invites obviousness attacks.
- Claim construction sensitivity: If key terms are easy to construe narrowly, defendants gain leverage.
- Historical litigation record: Patents that have survived PTAB challenges or prior district court scrutiny tend to attract more favorable settlement dynamics.
Decision-use framing: In licensing and investment contexts, the “strength” question is usually operationalized as expected probability of final injunction or delayed launch outcome.
Which companies are competing with MSN on this ANDA, and does the litigation affect the competitive landscape?
Answer: The docket identifies MSN as the ANDA defendant. Co-defendants and other generics can exist in the ecosystem, but competitive impact is driven by whether MSN is the first credible challenger and by the breadth of the injunction risk.
Competitive dynamics that typically follow
- If Celgene wins early or secures a strong settlement, other entrants often pause.
- If MSN narrows asserted patents or succeeds on invalidity for key claims, subsequent ANDAs can accelerate.
Analysis: The case can function as a signal for the rest of the generic market about which patent types are most vulnerable.
What manufacturing/IP barriers can delay an eventual generic launch?
Answer: For formulation and manufacturing method patents, generic readiness depends on:
- replicating process conditions,
- meeting impurity and stability targets tied to claim language,
- and staying outside process claim scopes if asserted.
At-risk launch constraints
Even if MSN clears the patent barrier, it still must meet:
- FDA Chemistry Manufacturing Controls expectations,
- and any bioequivalence requirements.
Patent-to-process translation: If the asserted claims include process limitations, manufacturing changes may not be sufficient unless they map to claim carve-outs.
How does this litigation compare with other Celgene ANDA patent cases?
Answer: Celgene’s pattern in ANDA litigation generally centers on enforcing Orange Book-listed patents through:
- infringement allegations tied to composition/formulation/method claims,
- and settlements that manage launch dates.
Comparable litigation patterns
Across similar cases involving Celgene in the Hatch-Waxman framework, courts commonly hinge outcomes on:
- claim construction,
- expert mapping to ANDA product attributes,
- and invalidity arguments tied to prior art disclosures.
Business relevance: If Celgene’s asserted patents in this docket align with commonly enforced claim families, settlement and launch timing often follow predictable trajectories.
Key Takeaways
- Celgene v. MSN (1:23-cv-00699) is an ANDA-driven patent infringement suit, with market impact tied to which Orange Book patents were asserted and how claim construction narrows the infringement and invalidity landscape.
- Generic launch risk depends less on docket existence and more on: (i) the asserted patent count and types (composition/formulation vs. method-of-use), (ii) claim construction outcomes, and (iii) whether a settlement includes a firm launch covenant.
- Decision focus for business and litigation teams: track claim construction, dispositive motions, and any narrowing stipulations, as these are the most predictive milestones for whether MSN can launch after stays/exclusivities end.
- Competitive signal: the outcome influences other ANDA entrants’ risk models, especially where the same patent family or similar claim scope is at issue in parallel challenges.
FAQs
1) What does a docket like 1:23-cv-00699 indicate about FDA timing for MSN?
It indicates a Hatch-Waxman-style patent dispute tied to an ANDA certification that can trigger a stay and delay launch depending on litigation outcome and settlement terms.
2) How do method-of-use patents change the settlement leverage compared with composition patents?
Method-of-use cases can sometimes be mitigated by label carve-outs, so settlements often hinge on label scope more than manufacturing replication.
3) What milestone most quickly changes generic launch probability in ANDA litigation?
Claim construction (Markman) because it defines claim scope and drives the infringement/invalidity workstreams.
4) Can a generic launch if it does not copy the exact manufacturing process?
If asserted claims include process steps or manufacturing limitations, changes can matter. If patents are composition-only, process deviations may not help unless they change the claimed product attributes.
5) What types of outcomes lead to a rapid resolution in ANDA patent suits?
Early narrowing of asserted claims, dispositive rulings on invalidity or non-infringement, and stipulations that render remaining disputes non-material.
References (APA)
- U.S. District Court docket, Celgene Corporation v. MSN Laboratories Private Limited, 1:23-cv-00699.
More… ↓
